US FDA slaps import alert on Dabur India's Dadra plant over data integrity, sanitation lapses
The US drug regulator has issued an import alert against Dabur India's Dadra and Nagar Haveli facility following an inspection that flagged falsified records, data integrity gaps and sanitation failures. Dabur says there is no material financial or operational hit and domestic products remain unaffected, with corrective action plans now submitted to the FDA.
What happened
US FDA issued an import alert on Dabur India's Dadra and Nagar Haveli plant after inspection flagged data integrity, falsified records, and sanitation lapses.
Key facts
- 140 years
- 30 feet
Why this matters
Watch for opportunistic positioning as Dabur's Dadra setback opens shelf space for rival Indian exporters and could pressure Dabur toward contract manufacturing tie-ups or US-based capacity deals to bridge the gap.